Profile Response Detail

Molecular Profile KRAS G13X
Therapy Panitumumab
Indication/Tumor Type colorectal cancer
Response Type resistant
Create By spatt
Update By smockus

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G13X colorectal cancer resistant Panitumumab FDA contraindicated Actionable Vectibix (panitumumab) treatment of colorectal cancer patients with KRAS exon 2, codon 13 mutations is contraindicated (FDA.gov). detail...
KRAS G13X colorectal cancer resistant Panitumumab Phase III Actionable In a Phase III trial, Vectibix (panitumumab) did not demonstrate efficacy in patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 (PMID: 18316791; NCT00113763). 18316791
PubMed Id Reference Title Details
FDA.gov Full reference...
(18316791) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Full reference...